124 related articles for article (PubMed ID: 36917968)
1. Measurement of Complement Activation via Plasma-Soluble C5b-9 Comparison with Terminal Complement Complex Staining in a Series of Kidney Biopsies.
Wijaya C; Burns C; Hall S; Farmer M; Jones D; Rowlandson M; Choi P; Formby M; de Malmanche T
Kidney Blood Press Res; 2023; 48(1):220-230. PubMed ID: 36917968
[TBL] [Abstract][Full Text] [Related]
2. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.
Wilson HR; Medjeral-Thomas NR; Gilmore AC; Trivedi P; Seyb K; Farzaneh-Far R; Gunnarsson I; Zickert A; Cairns TD; Lightstone L; Cook HT; Pickering MC
Kidney Int; 2019 Mar; 95(3):655-665. PubMed ID: 30655025
[TBL] [Abstract][Full Text] [Related]
3. Levels of SC5b--9 complement complex in plasma and synovial fluid of patients with rheumatic disease.
Rus V; Malide D; Boloşiu HD; Parasca I; Duţu AL
Med Interne; 1990; 28(4):305-10. PubMed ID: 2100875
[TBL] [Abstract][Full Text] [Related]
4. The pathobiology of the terminal complement complexes.
Dalmasso AP; Falk RJ; Raij L
Complement Inflamm; 1989; 6(1):36-48. PubMed ID: 2650989
[TBL] [Abstract][Full Text] [Related]
5. Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease.
Ma R; Cui Z; Liao YH; Zhao MH
J Clin Immunol; 2013 Jan; 33(1):172-8. PubMed ID: 22941511
[TBL] [Abstract][Full Text] [Related]
6. Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.
Tiller G; Lammerts RGM; Karijosemito JJ; Alkaff FF; Diepstra A; Pol RA; Meter-Arkema AH; Seelen MA; van den Heuvel MC; Hepkema BG; Daha MR; van den Born J; Berger SP
Front Immunol; 2022; 13():845301. PubMed ID: 35493506
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic roles of urinary kidney injury molecule 1 and soluble C5b-9 in acute tubulointerstitial nephritis.
Zhao WT; Huang JW; Sun PP; Su T; Tang JW; Wang SX; Liu G; Yang L
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F584-F592. PubMed ID: 31291122
[TBL] [Abstract][Full Text] [Related]
8. Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.
Koopman JJE; van Essen MF; Rennke HG; de Vries APJ; van Kooten C
Front Immunol; 2020; 11():599974. PubMed ID: 33643288
[TBL] [Abstract][Full Text] [Related]
9. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement.
Hugo F; Krämer S; Bhakdi S
J Immunol Methods; 1987 May; 99(2):243-51. PubMed ID: 3584995
[TBL] [Abstract][Full Text] [Related]
10. Soluble terminal complement activation fragment sC5b-9: a new serum biomarker for traumatic brain injury?
Parry J; Hwang J; Stahel CF; Henderson C; Nadeau J; Stacey S; Beauchamp K; Moore EE; Stahel PF
Eur J Trauma Emerg Surg; 2021 Oct; 47(5):1491-1497. PubMed ID: 32451568
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology.
Mollnes TE; Harboe M
Scand J Immunol; 1987 Oct; 26(4):381-6. PubMed ID: 3685888
[TBL] [Abstract][Full Text] [Related]
12. Plasma terminal complement complexes in acute poststreptococcal glomerulonephritis.
Matsell DG; Roy S; Tamerius JD; Morrow PR; Kolb WP; Wyatt RJ
Am J Kidney Dis; 1991 Mar; 17(3):311-6. PubMed ID: 1996575
[TBL] [Abstract][Full Text] [Related]
13. A simple immunoradiometric assay for the terminal SC5b-9 complex of human complement.
Bhakdi S; Muhly M
J Immunol Methods; 1983 Feb; 57(1-3):283-9. PubMed ID: 6827108
[TBL] [Abstract][Full Text] [Related]
14. Serum and plasma levels of Ba, but not those of soluble C5b-9, might be affected by renal function in chronic kidney disease patients.
Yamane R; Yasuda Y; Oshima A; Suzuki Y; Kojima H; Kim H; Fukui S; Maruyama S; Ito Y; Mizuno M
BMC Nephrol; 2023 Feb; 24(1):26. PubMed ID: 36732701
[TBL] [Abstract][Full Text] [Related]
15. Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.
Koski CL; Sanders ME; Swoveland PT; Lawley TJ; Shin ML; Frank MM; Joiner KA
J Clin Invest; 1987 Nov; 80(5):1492-7. PubMed ID: 3680509
[TBL] [Abstract][Full Text] [Related]
16. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation.
de Vries DK; van der Pol P; van Anken GE; van Gijlswijk DJ; Damman J; Lindeman JH; Reinders ME; Schaapherder AF; Kooten Cv
Transplantation; 2013 Mar; 95(6):816-20. PubMed ID: 23348894
[TBL] [Abstract][Full Text] [Related]
17. Differential contributions of the C5b-9 and C5a/C5aR pathways to microvascular and macrovascular thrombosis in complement-mediated thrombotic microangiopathy patients.
Liu X; Hu Y; Yu X; Tan Y; Yu F; Chen M; Zhao M
Clin Immunol; 2024 Feb; 259():109871. PubMed ID: 38101498
[TBL] [Abstract][Full Text] [Related]
18. Terminal complement complex (TCC) and S-protein (vitronectin) on follicular dendritic cells in human lymphoid tissues.
Halstensen TS; Mollnes TE; Brandtzaeg P
Immunology; 1988 Oct; 65(2):193-7. PubMed ID: 2461343
[TBL] [Abstract][Full Text] [Related]
19. Activation of final complement components after kidney transplantation as a marker of delayed graft function severity.
Arias-Cabrales CE; Riera M; Pérez-Sáez MJ; Gimeno J; Benito D; Redondo D; Burballa C; Crespo M; Pascual J; Rodríguez E
Clin Kidney J; 2021 Apr; 14(4):1190-1196. PubMed ID: 33841865
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study of the C5b-9 complex of complement in human kidneys.
Hinglais N; Kazatchkine MD; Bhakdi S; Appay MD; Mandet C; Grossetete J; Bariety J
Kidney Int; 1986 Sep; 30(3):399-410. PubMed ID: 3537447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
